FimmCyte, a pioneering women’s health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s most advanced program is a non-hormonal disease modifying treatment for endometriosis.
FimmCyte is a spin-off company from the University of Zürich and the University Hospital Zürich, the Lab of Prof. Brigitte Leener, and was founded in 2022 by Valentina Vongrad and Mohaned Shilaih. The pre-clinical stage biotechnology company focusses on the development of novel treatments for women’s health and beyond. Through tailored biotechnological approaches, FimmCyte reprograms the immune system to modify the underlying target diseases.
The company is developing the first disease modifying treatment for endometriosis and the program is soon to advance into IND enabling activities.
